Sai Life Sciences joins the ‘COVID Moonshot’ project

▴ medicircle-sai-life-sciences-joins-the-covid-moonshot-project
Sai Life Sciences joins the global ‘COVID Moonshot’ project

Sai Life Sciences, one of the fastest growing (CDMO in English for development and contract manufacturing organization) manufacturers in India, announced today that it is collaborating with the COVID Moonshot project which aims to provide a antiviral drug candidate effective against COVID-19. With in-kind support from a team of medical chemists and support infrastructure, Sai Life Sciences will help synthesize and profile analogs for New Chemical Entities (NCE) and other previously known compounds tested on other viruses.

PostEra, a biotechnology company specializing in machine learning for drug discovery, is leading this initiative. Leading experts from the fields of computer-based drug discovery, chemical synthesis and biochemical testing join them. In the three months since its launch in February this year, the team has already identified more than 60 experimentally confirmed "fragments" that effectively target a key protein associated with COVID-19. The team has now launched a participatory production initiative to accelerate the design of potential drug candidates from these fragments and has received more than 4,000 contributions from people around the world.

Welcoming Sai Life Sciences to the consortium, Aaron Morris, CEO of PostEra, said: “We are extremely grateful to Sai Life Sciences for the contribution they are making to this project. They help us take the most promising participatory production ideas from the Moonshot platform and transform them into chemical reality. It is a generosity like this that gives us hope that the dazzling launch of this project could obtain a revolutionary result in the context of our search for an effective antiviral against COVID ”.

Speaking about the company's participation in the project, Krishna Kanumuri, CEO and Executive Director of Sai Life Sciences, said: “We are delighted to join this leading global initiative. The consortium's approach to finding treatments for patients in the fight against COVID-19 is a commendable cause, which fits very well with our objective of working with partners to accelerate solutions that improve life. "

Over the past twenty years, Sai Life Sciences has built a portfolio of new chemical entity discovery services based on a solid chemical synthesis platform. Today, the company provides innovative biotechnology and pharmaceutical companies with the full range of discovery services, from identifying and validating targets to new research drugs (IND in English) and also encompass a solid set of capabilities for the development of NCEs and manufacturing in line with current good practice in this area.

Tags : #SaiLifeSciences #CovidMonnshot #GlobalProgram

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024